Banner Alzheimer’s Institute
Novartis and Amgen halt trials into Alzheimer’s drug after patients get worse
July 12, 2019Medical Communications Alzheimer's, Amgen, Banner Alzheimer's Institute, Novartis, dementia, pharma, research
Novartis, Amgen and Banner Alzheimer’s Institute have dropped a study into investigational Alzheimer’s drug CNP520 (umibecestat) after some patient’s conditions …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
